Eur J Cancer:高水平超敏C反应蛋白在肺癌患者中的影响的研究进展

2017-05-07 MedSci MedSci原创

许多文献报道,血中高水平的超敏C反应蛋白(CRP)是导致心血管疾病、慢性阻塞性肺疾病、癌症等患者生存期缩短的原因之一。在Eur J Cancer杂志上的一篇文章报道,研究者对可行手术治疗的肺癌患者,其血中CPR基线及术后水平的影响进行了调查研究。该研究对象为2003到2015年期间1750名肺癌全切术的患者,测量其基线水平的CRP水平,及术后3天的CRP水平。按照0个危险因素(N=593)、1个危

许多文献报道,血中高水平的超敏C反应蛋白(CRP)是导致心血管疾病、慢性阻塞性肺疾病、癌症等患者生存期缩短的原因之一。在Eur J Cancer杂志上的一篇文章报道,研究者对可行手术治疗的肺癌患者,其血中CPR基线及术后水平的影响进行了调查研究。

该研究对象为2003到2015年期间1750名肺癌全切术的患者,测量其基线水平的CRP水平,及术后3天的CRP水平。按照0个危险因素(N=593)、1个危险因素(N=658)、2个危险因素(N=553)对这些患者进行分类,并通过适当的Cox比例风险模型,应用?Kaplan-Meier?死亡曲线、校正危险比(HR)、95%置信区间(CI)对高水平CRP作用进行评估。

0个危险因素组的累计5年生存率为67%,1个危险因素组为58%,2个危险因素组为41%(P<0.0001)。总的5年死亡率风险在有1个危险因素或2个危险因素的患者中较高。肿瘤淋巴结转移组及非吸烟患者中,观察到了其对生存率有着重要影响。在有2项危险因素的患者中,其术后30天的死亡率明显升高(aHR 2.2% versus0.6%,p<0.0475)。

该研究者最后得出结论:PCR的基线水平及术后水平,具有预测可行手术治疗的各期肺癌患者的中位死亡率及长期死亡率的作用。

原始出处:

Pastorino U, Morelli D, Leuzzi G,et al.Baseline and postoperative C-reactive protein levels predict mortality in operable lung cancer.Eur J Cancer. 2017 May 1;79:90-97. doi: 10.1016/j.ejca.2017.03.020.

本文系梅斯医学(medsci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2075654, encodeId=a8cd20e565411, content=<a href='/topic/show?id=6c5b92854ec' target=_blank style='color:#2F92EE;'>#超敏C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92854, encryptionId=6c5b92854ec, topicName=超敏C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Sat Jun 03 22:34:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990580, encodeId=b4651990580ce, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Dec 24 03:34:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196252, encodeId=e702196252c8, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Wed May 10 15:09:36 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297815, encodeId=1120129e81567, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 08 15:34:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380791, encodeId=0e511380e918a, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon May 08 15:34:00 CST 2017, time=2017-05-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2075654, encodeId=a8cd20e565411, content=<a href='/topic/show?id=6c5b92854ec' target=_blank style='color:#2F92EE;'>#超敏C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92854, encryptionId=6c5b92854ec, topicName=超敏C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Sat Jun 03 22:34:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990580, encodeId=b4651990580ce, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Dec 24 03:34:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196252, encodeId=e702196252c8, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Wed May 10 15:09:36 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297815, encodeId=1120129e81567, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 08 15:34:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380791, encodeId=0e511380e918a, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon May 08 15:34:00 CST 2017, time=2017-05-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2075654, encodeId=a8cd20e565411, content=<a href='/topic/show?id=6c5b92854ec' target=_blank style='color:#2F92EE;'>#超敏C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92854, encryptionId=6c5b92854ec, topicName=超敏C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Sat Jun 03 22:34:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990580, encodeId=b4651990580ce, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Dec 24 03:34:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196252, encodeId=e702196252c8, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Wed May 10 15:09:36 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297815, encodeId=1120129e81567, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 08 15:34:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380791, encodeId=0e511380e918a, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon May 08 15:34:00 CST 2017, time=2017-05-08, status=1, ipAttribution=)]
    2017-05-10 绛珠草小姐

    学习了,谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2075654, encodeId=a8cd20e565411, content=<a href='/topic/show?id=6c5b92854ec' target=_blank style='color:#2F92EE;'>#超敏C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92854, encryptionId=6c5b92854ec, topicName=超敏C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Sat Jun 03 22:34:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990580, encodeId=b4651990580ce, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Dec 24 03:34:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196252, encodeId=e702196252c8, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Wed May 10 15:09:36 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297815, encodeId=1120129e81567, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 08 15:34:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380791, encodeId=0e511380e918a, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon May 08 15:34:00 CST 2017, time=2017-05-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2075654, encodeId=a8cd20e565411, content=<a href='/topic/show?id=6c5b92854ec' target=_blank style='color:#2F92EE;'>#超敏C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92854, encryptionId=6c5b92854ec, topicName=超敏C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Sat Jun 03 22:34:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990580, encodeId=b4651990580ce, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Sun Dec 24 03:34:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196252, encodeId=e702196252c8, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/1A51842815047D40BFDAA8D69AA8E519/100, createdBy=fd7f2029163, createdName=绛珠草小姐, createdTime=Wed May 10 15:09:36 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297815, encodeId=1120129e81567, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Mon May 08 15:34:00 CST 2017, time=2017-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380791, encodeId=0e511380e918a, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon May 08 15:34:00 CST 2017, time=2017-05-08, status=1, ipAttribution=)]

相关资讯

Atherosclerosis:超敏C反应蛋白升高与无症状性颈动脉狭窄相关

背景:炎症在动脉粥样硬化的病理生理过程中起着关键的作用。超敏C反应蛋白(hs-CRP),尤其是长期hs-CRP的浓度与和中国健康成人无症状的颈动脉狭窄(ACAS)关系尚不清楚。本研究的目的是评估hs-CRP水平与中国人群的ACAS发生的关系。方法:本研究招募了5349名年龄≥40岁(40.36%为女性)患者,所有受试者无卒中史。双侧颈动脉超声检查评估颈动脉狭窄的程度。根据hs-CRP水平,将受试者